Mechanistic PKPD Modeling to Describe Cytokine Release Associated with CD3 T-cell Engager Therapies

Overview

Journal Front Immunol

Date 2025 Feb 3

PMID 39896804

Authors

Apolline Lefevre

Zinnia P Parra-Guillen

Inaki F Troconiz

Christophe Boetsch

Nicolas Frances

Affiliations

Soon will be listed here.

Abstract

Introduction: T-cell engagers (TCE), a therapeutic class of cancer immunotherapy (CIT), offer a novel approach to cancer treatment by harnessing and reactivating the patient's immune system to eradicate tumor cells. However, the use of TCE in the clinic can lead to severe side effects, including cytokine release syndrome (CRS). Therefore, innovative dosing strategies need to be implemented to mitigate the risk of developing CRS.

Method: In the presented work, a mechanistic pharmacokinetics/pharmacodynamics (PKPD) model describing cytokine release following TCE therapy has been developed combining literature knowledge and preclinical data. The model was developed to explore and test hypotheses regarding the mechanisms behind the decrease of cytokine release following two repeated TCE administrations.

Results: The model is able to successfully reproduce the observed dynamics of cytokine levels associated with the initial and subsequent TCE doses, accounting for different dosing intervals. In addition, the model suggests a mechanism of action that uncouples cytokine release from tumor cell killing.

Discussion: This model provides an initial mechanistic framework to support the design of experiments and paves the way for the application of mathematical modeling to support clinical dosing regimen selection of any TCE.

References

Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E . Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. J Pharm Sci. 2021; 111(4):1208-1218. DOI: 10.1016/j.xphs.2021.12.019. View

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M . Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5(12):1731-40. DOI: 10.1016/j.intimp.2005.05.010. View

Ma H, Wang H, Sove R, Jafarnejad M, Tsai C, Wang J . A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor. AAPS J. 2020; 22(4):85. PMC: 7293198. DOI: 10.1208/s12248-020-00450-3. View

Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler H, Schlosser H, Schlaak M . Cytokine release syndrome. J Immunother Cancer. 2018; 6(1):56. PMC: 6003181. DOI: 10.1186/s40425-018-0343-9. View

Ball K, Dovedi S, Vajjah P, Phipps A . Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023; 15(1):2181016. PMC: 9980545. DOI: 10.1080/19420862.2023.2181016. View

Hosseini I, Gadkar K, Stefanich E, Li C, Sun L, Chu Y . Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020; 6(1):28. PMC: 7455723. DOI: 10.1038/s41540-020-00145-7. View

Parra-Guillen Z, Schmid U, Janda A, Freiwald M, Troconiz I . Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing Antibody. Clin Pharmacol Ther. 2019; 107(3):597-606. DOI: 10.1002/cpt.1648. View

Leclercq G, Alberti Servera L, Danilin S, Challier J, Steinhoff N, Bossen C . Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology. 2022; 11(1):2039432. PMC: 8855852. DOI: 10.1080/2162402X.2022.2039432. View

Van De Vyver A, Marrer-Berger E, Wang K, Lehr T, Walz A . Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?. Clin Cancer Res. 2021; 27(22):6083-6094. DOI: 10.1158/1078-0432.CCR-21-0470. View

10.

Kuemmel C, Yang Y, Zhang X, Florian J, Zhu H, Tegenge M . Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation. CPT Pharmacometrics Syst Pharmacol. 2019; 9(1):21-28. PMC: 6966181. DOI: 10.1002/psp4.12479. View

11.

Jiang X, Chen X, Jaiprasart P, Carpenter T, Zhou R, Wang W . Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans. Eur J Pharm Sci. 2020; 146:105260. DOI: 10.1016/j.ejps.2020.105260. View

12.

Lythe G, Callard R, Hoare R, Molina-Paris C . How many TCR clonotypes does a body maintain?. J Theor Biol. 2015; 389:214-24. PMC: 4678146. DOI: 10.1016/j.jtbi.2015.10.016. View

13.

Saber H, Del Valle P, Ricks T, Leighton J . An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol. 2017; 90:144-152. DOI: 10.1016/j.yrtph.2017.09.001. View

14.

Shah D, Soper B, Shopland L . Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. 2023; 14:1190379. PMC: 10248525. DOI: 10.3389/fimmu.2023.1190379. View

15.

Middelburg J, Kemper K, Engelberts P, Labrijn A, Schuurman J, van Hall T . Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel). 2021; 13(2). PMC: 7829968. DOI: 10.3390/cancers13020287. View

16.

Dolina J, Van Braeckel-Budimir N, Thomas G, Salek-Ardakani S . CD8 T Cell Exhaustion in Cancer. Front Immunol. 2021; 12:715234. PMC: 8330547. DOI: 10.3389/fimmu.2021.715234. View

17.

Sancho-Araiz A, Mangas-Sanjuan V, Troconiz I . The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. Pharmaceutics. 2021; 13(7). PMC: 8309057. DOI: 10.3390/pharmaceutics13071016. View

18.

Shimu A, Wei H, Li Q, Zheng X, Li B . The new progress in cancer immunotherapy. Clin Exp Med. 2022; 23(3):553-567. PMC: 10284946. DOI: 10.1007/s10238-022-00887-0. View

19.

Staflin K, Zuch de Zafra C, Schutt L, Clark V, Zhong F, Hristopoulos M . Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. JCI Insight. 2020; 5(7). PMC: 7205277. DOI: 10.1172/jci.insight.133757. View

20.

Yu S, Zhang J, Yan Y, Yao X, Fang L, Xiong H . A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019; 38(1):355. PMC: 6694677. DOI: 10.1186/s13046-019-1354-1. View